Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05478863 · ClinicalTrials.gov registry record · Early Phase 1
The Pharmacodynamics of Cannabinoid-Caffeine Combinations
A Early Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT05478863: Completed Early Phase 1 study, sponsored by Johns Hopkins University.
NCT05478863 is a Early Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05478863, a Early Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Cannabis and caffeine are two of the most commonly consumed psychoactive substances in the world, with many consumers reporting positive impacts on energy, alertness, and focus. Preliminary evidence has suggested that cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, may mitigate the negative side effects of caffeine (e.g., feeling jittery) without impacting positive or desired effects. CBD also shows potential in reducing undesirable acute effects (e.g., anxiety) of delta-9-tetrahydrocannabinol (THC), the primary intoxicating cannabinoid found in cannabis. Despite these promising findings, little is known about the potential effects of THC, caffeine, and CBD in combination. This double-blind, randomized, placebo-controlled, within-subject crossover study will assess the effects of combinations of THC, CBD, and caffeine (i.e., THC only; THC + caffeine; THC + CBD + caffeine) on subjective energy, arousal, and cognitive performance.
Interventions
- DRUG Oral Placebo
- DRUG Oral THC
- DRUG Oral CBD
- DRUG Oral Caffeine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-01-20 |
| Est. Completion | 2024-10-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05478863
The ClinicalTrials.gov registry entry for NCT05478863 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Oral Placebo is the first listed.
NCT05478863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05478863 about?
NCT05478863 is a clinical study titled "The Pharmacodynamics of Cannabinoid-Caffeine Combinations". Cannabis and caffeine are two of the most commonly consumed psychoactive substances in the world, with many consumers reporting positive impacts on energy, alertness, and focus. Preliminary evidence has suggested that cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, may mitigat...
What is the current status of trial NCT05478863?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2023-01-20. Estimated completion is 2024-10-02.
What interventions are being tested in trial NCT05478863?
The interventions under investigation include: Oral Placebo (DRUG), Oral THC (DRUG), Oral CBD (DRUG), Oral Caffeine (DRUG).
Who is sponsoring clinical trial NCT05478863?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.